Detemination of the prevalence of aspirin and clopidogrel resistances in patients with coronary artery disease by using various platelet-function tests

Korean Journal of Laboratory Medicine

Volumn 30, Issue 5, 2010, Pages 460-468

  Woo, Kwang Sook ^a   Kim, Bo Ram ^a   Kim, Ji Eun ^a   Goh, Ri Young ^a   Yu, Long Hao ^b   Kim, Moo Hyun ^b   Han, Jin Yeong ^a,c  

^a Departments of Laboratory Medicine   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Dong A University   (South Korea)

Author keywords

Aspirin; Clopidogrel; Platelet function tests; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DRUG DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TETRAZOLE DERIVATIVE; TICLOPIDINE;

AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CORONARY ARTERY DISEASE; DRUG COMBINATION; DRUG EFFECT; DRUG ELUTING STENT; DRUG RESISTANCE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TETRAZOLES; TICLOPIDINE;

EID: 78049264448     PISSN: 15986535     EISSN: None     Source Type: Journal    
DOI: 10.3343/kjlm.2010.30.5.460     Document Type: Article

References (40)

1. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of Clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
2. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
3. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.
4. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with Clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9-14.
5. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
6. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
7. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Panicda R, et al. Impact of platelet reactivity after Clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49:2312-7.
8. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820-6.
9. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4:542-9.
10. Lordkipanidzé M, Pharand C, Palisaitis DA, Diodati JG. Aspirin resistance: truth or dare. Pharmacol Ther 2006;112:733-43.
11. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and Clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag 2009;5:965-72.
12. Azam SM and Jozic J. Variable platelet responsiveness to aspirin and Clopidogrel: role of platelet function and genetic polymorphism testing. Transl Res 2009;154:309-13.
13. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93.
14. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-44.
15. Cardinal DC and Rower RJ. The electronic aggregometen a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980;3:135-58.
16. Schwarz UK Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of tidopidine/clopidogrel effects. Thromb Haemost 1999;82:1145-52.
17. Dussaillant NG, Zapata MM, Fardella BP, Conte LG, Cuneo VM. Frequency and characteristics of aspirin resistance in Chilean cardiovascular patients. Rev Med Chil 2005;133:409-17.
18. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
19. Harrison P, Segal H, Blasbery K, Furtado C, Silver L, Rothwell PM. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 2005;36:1001-5.
20. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic Clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49:657-66.
21. Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFAASA system. Point Care 2004;3:77-82.
22. Malinin A, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004;15:295-301.
23. Lee K, Lee SW, Lee JW, Kim SY, Youn YJ, Ahn MS, et al. The significance of Clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drugeluting stent implantation. Korean Circ J 2009;39:512-8.
24. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59:295-302.
25. Nicholson NS, Panzer-Knodle SG, Haas NF, Taite BB, Szalony JA, Page JD, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-8.
26. Michelson AD, Frelinger AL 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol 2006;98:4N-10N.
27. Mueller T, Dieplinger B, Poelz W, Calatzis A, Haltmayer M. Utility of whole blood impedance aggregometry for the assessment of dopidogrel action using the novel Multiplate analyzer-comparison with two flow cytometric methods. Thromb Res 2007;121:249-58.
28. Wang TH, Bhatt DL, Topol EJ. Aspirin and dopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27:647-54.
29. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
30. Gurbel PA and Tantry US. Clopidogrel resistance? Thromb Res 2007; 120311-21.
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, BarreraRamirez Q Sabaté M, et al. Identification of low responders to a 300mg Clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101-8.
32. Marcucd R, Panicda R, Antonucd E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006;98:1156-9.
33. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of dopidogrel non-responders among patients with stable angina pedoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-7.
34. Collet JP and Montalescot G. Platelet function testing and implications for clinical practice. J Cardiovasc Pharmacol Ther 2009;14:157-69.
35. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year followup of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993;71:397-403.
36. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et aL Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 2005;45:1753-6.
37. Gurbel PA, Bilden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effed on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46:1827-32.
38. Motovska Z, Widimsky P, Petr R, Bilkova D, Marinov I, Simek S, et al. Optimal pretreatment timing for high load dosing (600 mg) of dopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness. Int J Cardiol. Forthcoming 2009.
39. Price MJ, Endemann S, Gollapudi RR, Valenda R, Stinis CT, Levisay JP, et al. Prognostic significance of post-dopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.
40. Frere C, Cuisset T, Quilid J, Camoin L, Carvajal J, Morange PE, et al. ADP-induced platelet aggregation and platelet readivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838-43.